You are here

Psychemedics Announces 2Q Record Revenues

Declares 88th Consecutive Quarterly Dividend

ACTON, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2018.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of August 7, 2018, to be paid on August 17, 2018.  This will be the Company’s 88th consecutive quarterly dividend.

The Company’s revenue for the quarter ended June 30, 2018 was $10.8 million versus $9.7 million for the comparable period in 2017, an increase of 11%.  Net income for the quarter ended June 30, 2018 was $1.2 million or $0.21 per diluted share, versus $0.9 million or $0.16 per diluted share, for the comparable period last year, an increase of 30%.  Revenue for the six months ended June 30, 2018 was $21.7 million versus $19.9 million for the comparable period in 2017, an increase of 9%.  Net income for the six months ended June 30, 2018 and 2017 was $2.4 million or $0.44 per diluted share.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said,

"Second quarter revenues were a record for any second quarter in the Company's history. Our domestic revenues continued to show strong growth, increasing 15%, which, as in the first quarter, was largely attributable to our Transportation and Oil and Gas market segments. Our international business (primarily Brazil) was up 4%. This was significantly impacted by a change in the Brazil exchange rate. International revenue would have been up 16% for the quarter compared to the same period in 2017 and total revenue would have increased 15%, if the exchange rate had remained the same.

"Earnings growth for the quarter of 30% was primarily driven by increased revenue.  In addition, the Company’s effective tax rate decreased from 47% in the second quarter of 2017 to 43% in the current quarter. This reflects the reduction in the U.S. federal income tax rate which is partially offset by Brazilian income taxes.  While we were encouraged with the strong increase in earnings, they would have been even better without the negative impact of $0.04 per diluted share from the change in the Brazil exchange rate.

"We are encouraged by the continuing strength and momentum in our domestic business and also look forward to the expansion of the Brazil market later this year when professional drivers are required to renew their licenses every 2 1/2 years instead of the current 5 years. This expansion is by law and would virtually double the market size as it unfolds.

“The Company’s balance sheet remains strong with $7.7 million in cash and $9.3 million of working capital.  The total equipment financing obligation outstanding was $2.9 million as of June 30, 2018.  Our directors share our confidence in the future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we grow.  Therefore, we are pleased to declare our quarterly dividend $0.18 per share. This dividend represents our 88th consecutive quarterly dividend.”

Neil Lerner
Vice President of Finance
(978) 206-8220

Psychemedics Corporation is the world’s largest provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods.

The Psychemedics web site is

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995:  From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties.  In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, cash flows, dividends, future business, growth opportunities, profitability, pricing, new accounts, customer base, market share, test volume, sales and marketing strategies, U.S. and foreign drug testing laws and regulations and the enforcement of such laws and regulations, required investments in plant, equipment and people and new test development) may be "forward looking" statements.  Actual results may differ from those stated in any forward-looking statements.  Factors that may cause such differences include but are not limited to risks associated with the development of markets for new products and services offered, costs of capacity expansion, U.S. and foreign government regulation, including but not limited to FDA regulations, Brazilian laws and regulations, proposed laws and regulations, currency risks, R&D spending, competition (including, without limitation, competition from other companies pursuing the same growth opportunities), the Company’s ability to maintain its reputation and brand image, the ability of the Company to achieve its business plans, cost controls, leveraging of its global operating platform, risks of information technology system failures and data security breaches, the uncertain global economy, the Company’s  ability to attract, develop and retain executives and other qualified employees and independent contractors, including distributors, the Company’s ability to obtain and protect intellectual property rights, litigation risks, general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.  The forward-looking statements contained herein speak only of the Company's expecta­tions as of the date of this press release. The Company express­ly disclaims any obligation or undertaking to release publicly any updates or revi­sions to any such statement to reflect any change in the Company's expectations or any change in events, conditions, or circumstances on which any such statement is based.

Psychemedics Corporation
Consolidated Statements of Income
(in thousands, except per share amounts)
 Three Months Ended Six Months Ended 
 June 30, June 30, 
  2018   2017   2018   2017  
Revenues$  10,787  $  9,684  $  21,722  $  19,893  
Cost of revenues   5,615     5,075     11,195     9,968  
Gross profit   5,172     4,609     10,527     9,925  
Operating Expenses:        
  General & administrative   1,457     1,334     3,308     2,809  
  Marketing & selling   1,301     1,244     2,540     2,487  
  Research & development   358     321     717     651  
Total Operating Expenses   3,116     2,899     6,565     5,947  
Operating income   2,056     1,710     3,962     3,978  
Other income (expense)   24   (12)    56   (34) 
Net income before provision for income taxes   2,080     1,698     4,018     3,944  
Provision for income taxes   903     791     1,590     1,537  
Net income$  1,177  $  907  $  2,428  $  2,407  
Diluted net income per share$  0.21  $  0.16  $  0.44  $  0.44  
Dividends declared per share$  0.18  $  0.15  $  0.36  $  0.30  


Psychemedics Corporation
Consolidated Balance Sheets
(in thousands, except par value)
 June 30, December 31,
  2018   2017 
 Current Assets:   
  Cash and cash equivalents$  7,721  $  8,165 
  Accounts receivable, net of allowance for doubtful accounts   
     of $77 in 2018 and $64 in 2017   5,195     4,488 
  Prepaid expenses and other current assets   1,465     1,212 
Total Current Assets   14,381     13,865 
Fixed Assets, net of accumulated amortization and depreciation   
  of $13,181 in 2018 and $11,670 in 2017   11,129     11,811 
Other assets   915     832 
Total Assets$  26,425  $  26,508 
Current Liabilities:   
  Accounts payable$  1,117  $  398 
  Accrued expenses   3,014     2,870 
  Current portion of long-term debt   957     957 
Total Current Liabilities   5,088     4,225 
  Long-term debt   1,942     2,420 
  Deferred tax liabilities, long-term   1,138     1,243 
Total Liabilities   8,168     7,888 
Shareholders' Equity:   
  Preferred stock, $0.005 par value, 873 shares authorized,   
     no shares issued or outstanding --   -- 
  Common stock, $0.005 par value; 50,000 shares authorized   
     6,175 shares issued in 2018 and 6,160 shares issued in 2017   31     31 
  Accumulated other comprehensive loss (1,403)  (238)
  Additional paid-in capital   31,208     31,022 
  Accumulated deficit (1,497)  (2,113)
  Less - Treasury stock, at cost, 668 shares (10,082)  (10,082)
Total Shareholders' Equity   18,257     18,620 
Total Liabilities and Shareholders' Equity$  26,425  $  26,508 


Tuesday, July 24, 2018 - 17:30